Last updated: 11/04/2018 04:04:06
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
GSK study ID
683699/004
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of nine-weeks administration of three doses of SB-683699 in subjects with moderately to severely active crohn's disease
Trial description: This study will evaluate the effectiveness and safety of the investigational drug 683699 in treating subjects with moderately to severely active CD (Crohn's Disease).
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Not applicable
Allocation:
Randomized
Primary outcomes:
Number of participants who were responders at Week 6 of treatment
Timeframe: At Week 6
Secondary outcomes:
Number of participants with the indicated response at other time points
Timeframe: At Week 3
Number of participants in remission defined by a CDAI score < 150
Timeframe: Week 3 and 6
Number of participants with response or remission
Timeframe: At Week 3 and 6
Change from baseline in CDAI scores
Timeframe: Baseline (Day 1), Week 3, 6, 9, Early termination and follow-up ( Week 12)
Average rate of response for the CDAI during treatment at specified time points
Timeframe: Up to follow-up (Week 12)
Change from baseline in Harvey Bradshaw Index scores
Timeframe: Baseline (Day 1), Week 3, 6, 9, Early termination and follow-up (Week 12)
Improvements in Inflammatory Bowel Disease (IBD)-related Quality of Life (QoL) scores
Timeframe: Up to Week 12
Interventions:
Enrollment:
17
Primary completion date:
2006-10-07
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Crohn's Disease
Product
firategrast
Collaborators
Not applicable
Study date(s)
October 2004 to July 2006
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 65 years
Accepts healthy volunteers
No
- Diagnosed with CD and reconfirmed in previous 2 years by a radiologic or endoscopic assessment including histology.
- CDAI (Crohn's Disease Activity Index) score of 220-450 after 1 week of screening.
- Significantly abnormal laboratory tests or ECG (electrocardiogram) results.
- Current use of an elemental diet or parenteral nutrition.
Inclusion and exclusion criteria
Inclusion criteria:
- Diagnosed with CD and reconfirmed in previous 2 years by a radiologic or endoscopic assessment including histology.
- CDAI (Crohn's Disease Activity Index) score of 220-450 after 1 week of screening.
- CRP (C-Reactive Protein) level of >4mg at screening.
Exclusion criteria:
- Significantly abnormal laboratory tests or ECG (electrocardiogram) results.
- Current use of an elemental diet or parenteral nutrition.
- Clinically significant positive stool culture.
- Ongoing neoplastic disease of the bowel.
- Bowel perforation other than fistulae.
- Has an ileostomy or colostomy.
- Fixed symptomatic gastrointestinal (GI) stricture within 6 months or obstructive symptoms within 3 months of screening.
- Any bowel resection within 12 months of screening or bowel resection without subsequent demonstration of recurrence of active CD.
- More than 100cm of bowel resected.
- Non-curative bowel surgery with 2 months of screening.
- Symptoms attributed to short bowel syndrome.
- Uncontrolled bacterial, viral, or fungal infection or congenital or acquired immunodeficiency.
- Women who are pregnant, breast feeding, or planning to become pregnant during the study. Permitted medications:
- Less than or equal to 20mg/day oral corticosteroids for at least 4 weeks prior to screening and on stable doses for 2 weeks prior to screening.
- Azathioprine and 6-MP (6-Mercaptopurine) stable dose for 3 months prior to screening.
- 5-ASA (5-Aminosalicylic acid) stable dose for 1 month prior to screening. Prohibited medications:
- Greater than 20mg/day oral corticosteroids, or systemic intravenous corticosteroids, or antibiotics as a treatment for CD within 4 weeks prior to screening.
- Cyclosporine or methotrexate during the 2 months prior to screening.
- Infliximab or other biological treatments within 3 months prior to screening.
Trial location(s)
Location
GSK Investigational Site
Altoona, Pennsylvania, United States, 16602
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Charleston, South Carolina, United States, 29425
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Galveston, Texas, United States, 77555
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Charlotte, North Carolina, United States, 28207
Status
Terminated/Withdrawn
Showing 1 - 6 of 43 Results
Study documents
No study documents available.
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2006-10-07
Actual study completion date
2006-10-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website